Genetic Technologies (ASX:GTG) says it has been granted a US patent for the technology incorporated into GTG’s geneType COVID19 Risk Test.
The company said the test provides a probability that a person will develop severe symptoms requiring hospitalisation should they become infected.
CEO Simon Morris said, “The granting of this patent is another important step in securing the commercial opportunity for our geneType COVID-19 Risk Test.
"We believe there is a significant and realisable market for our COVID-19 Risk Test. In conjunction with our partners we are well-positioned to drive forward with our sales and marketing endeavours and potentially providing an improvement in health outcomes for patients at risk of developing severe COVID-19 disease.”
The COVID-19 Risk Test is designed to predict disease severity providing a risk score that can be used to understand a person’s risk of contracting a serious case of COVID-19.
The company said employers, governments and other public health entities may use the data to make informed decisions about disease risk, treatment options and guiding vaccination and booster priorities.
Genetic Technologies chief scientific officer Dr Richard Allman said, “The currently circulating omicron and delta SARS-CoV-2 variants are both highly transmissible and the Company believes that the geneType COVID-19 Risk Test will maintain broad applicability across variant types and complement current public health efforts in vaccine and booster uptake.”